Oppenheimer & Co. Inc. Sells 3,000 Shares of Genomic Health Inc. (GHDX)
Oppenheimer & Co. Inc. decreased its position in shares of Genomic Health Inc. (NASDAQ:GHDX) by 2.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,749 shares of the company’s stock after selling 3,000 shares during the period. Oppenheimer & Co. Inc.’s holdings in Genomic Health were worth $4,013,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Emerald Acquisition Ltd. purchased a new stake in Genomic Health during the second quarter worth about $1,983,000. Swiss National Bank raised its stake in Genomic Health by 2.3% in the second quarter. Swiss National Bank now owns 31,200 shares of the company’s stock worth $808,000 after buying an additional 700 shares in the last quarter. Columbus Circle Investors purchased a new stake in Genomic Health during the second quarter worth about $1,376,000. California State Teachers Retirement System raised its stake in Genomic Health by 4.0% in the second quarter. California State Teachers Retirement System now owns 39,167 shares of the company’s stock worth $1,014,000 after buying an additional 1,510 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Genomic Health by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 88,963 shares of the company’s stock worth $2,304,000 after buying an additional 2,315 shares in the last quarter. Institutional investors own 89.65% of the company’s stock.
Shares of Genomic Health Inc. (NASDAQ:GHDX) traded up 0.81% during mid-day trading on Tuesday, hitting $31.16. 109,940 shares of the company were exchanged. Genomic Health Inc. has a 12-month low of $22.00 and a 12-month high of $35.79. The stock’s market cap is $1.04 billion. The stock’s 50-day moving average price is $30.58 and its 200 day moving average price is $28.22.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, November 1st. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. The business earned $82.30 million during the quarter, compared to analysts’ expectations of $83.24 million. Genomic Health had a negative return on equity of 14.13% and a negative net margin of 5.77%. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.36) EPS. On average, equities analysts anticipate that Genomic Health Inc. will post ($0.46) EPS for the current fiscal year.
A number of research firms have recently issued reports on GHDX. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 25th. Canaccord Genuity reiterated a “buy” rating and set a $38.00 price objective on shares of Genomic Health in a research note on Friday, August 5th. Bank of America Corp. set a $28.00 price target on shares of Genomic Health and gave the stock a “sell” rating in a research note on Wednesday, August 3rd. Finally, Jefferies Group lifted their price target on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Genomic Health has a consensus rating of “Hold” and an average price target of $32.50.
In related news, insider Steven Shak sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $26.83, for a total value of $134,150.00. Following the completion of the sale, the insider now owns 332,207 shares of the company’s stock, valued at approximately $8,913,113.81. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO G Bradley Cole sold 8,290 shares of the business’s stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $30.59, for a total value of $253,591.10. Following the completion of the sale, the chief operating officer now directly owns 39,426 shares of the company’s stock, valued at approximately $1,206,041.34. The disclosure for this sale can be found here. 47.00% of the stock is owned by corporate insiders.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.